Page 16 - Biocon
Biocon launches insulin Glargine in disposable pens in Japan
The Japanese Glargine market is estimated to be around $144 million, Biocon said in a statement
 "Biocon launches insulin Glargine in disposable pens in Japan")
Biocon gains on launching Insulin Glargine in Japan
The stock was trading higher by 3% at Rs 732 on the National Stock Exchange at 09:27 AM.
Biosimilars: A shot in the arm for Biocon's future prescription
Its huge R&D spending on biosimilars, despite investor apathy, has started to show results
 "Biosimilars: A shot in the arm for Biocon's future prescription")
Biocon begins clinical trials for drug to treat rare eye disorder
The drug has been jointly developed with US-based QuarK Pharmaceuticals
 "Biocon begins clinical trials for drug to treat rare eye disorder")
Biocon, Quark get DCGI nod for trials of new eye disease drug
The companies also announced the randomisation of the first patient in India in the global Phase II/III study of the new drug candidate
 "Biocon, Quark get DCGI nod for trials of new eye disease drug")
Biocon hits new lifetime high
Since April 26, post March quarter results, the stock rallied 30% as compared to 3% rise in the S&P BSE Sensex
 "Biocon hits new lifetime high")
Mylan, Biocon confirm efficacy of trastuzumab biosimilar
Trastuzumab is indicated for treatment of a type of breast cancer, Biocon said
Yes Bank, BPCL, Biocon, Finolex Cables hit lifetime highs
HDFC Bank, Asian Paints, City Union Bank, Grasim Ind, IndusInd Bank, Pidilite Ind and Supreme Ind hit record highs
 "Yes Bank, BPCL, Biocon, Finolex Cables hit lifetime highs")
Biocon: Near-term positives priced in
Biosimilars in trial stages; once approved, these can lead to much larger gains
 "Biocon: Near-term positives priced in")
Biocon's Q4 net profit jumps 250% to Rs 361 crore on exceptional income
Amount of Rs 268 crore, allocated for research earlier, was shown as income after inking pact for rh insulin with Mexico-based firm
Biocon expects more filings this year for biosimilars, drugs
Q4 profit up 79% to Rs 361 crore; invests more on R&D
Street confidence rises on Biocon's insulin biosimilars
With expected filings of four insulin products in the current financial year, analysts have started upgrading their earnings estimates for the company
 "Street confidence rises on Biocon's insulin biosimilars")
Biocon nears 52-week high on heavy volumes
The stock up 9% to Rs 533 on the BSE, trading close its 52-week high of Rs 544 touched on January 5.
 "Biocon nears 52-week high on heavy volumes")
Biocon to co-develop and produce recombinant insulin for US market
Ties up with Mexico's PiSA for the insulin to tap the $2-billion US market
 "Biocon to co-develop and produce recombinant insulin for US market")
